{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:23:13Z","timestamp":1791310993653,"version":"4.3.1"},"reference-count":230,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Several urinary markers reflect disease severity and have the potential to support the management of heart failure (HF). Collecting urine samples is easy and inexpensive, and urine sample composition can be altered not only by underlying kidney impairments (i.e. filtration barrier damage and tubular injury) but also via neurohormonal and inflammatory activation, ageing, comorbidities, other medical conditions and pharmacological interventions. For instance, urinary sodium may help to predict the response to loop diuretic therapy in acute HF, while albuminuria is used as a risk marker and therapeutic target for the progression of cardiovascular and kidney diseases in chronic HF, especially when accompanied by kidney disease. However, these markers remain underutilized in clinical practice. This review paper underscores the role of urinary markers in HF, with a specific focus on: (i) the pathophysiologic mechanisms underlying urinary marker excretion, (ii) the prognostic values of urinary markers across diverse HF phenotypes and non-cardiovascular comorbidities (i.e. chronic kidney disease and diabetes), (iii) the impact of medical therapies on urinary markers, and (iv) existing knowledge gaps that challenge their implementation in clinical practice. The recommendations are aligned with current guidelines, evidence, and expert consensus.<\/jats:p>","DOI":"10.1002\/ejhf.70079","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T20:18:49Z","timestamp":1762201129000},"page":"2372-2396","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Urinary Markers in Heart Failure \u2013 Types, Timing and Thresholds.\n                    <i>European Journal of Heart Failure<\/i>\n                    Expert Consensus Document"],"prefix":"10.1093","volume":"27","author":[{"given":"Masatake","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tokyo medical university , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Cardiology Section, Winters Center for Heart Failure, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder Langeland","family":"Myhre","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet , Oslo ,","place":["Norway"]},{"name":"Department of Cardiology, Akershus University Hospital , L\u00f8renskog ,","place":["Norway"]},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Lopez Azor","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Majadahonda, Madrid ,","place":["Spain"]},{"name":"Departamento de Cardiolog\u00eda, Hospital Universitario Puerta de Hierro , Majadahonda, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Guzik","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Department of Intensive Cardiac Care, Wroclaw Medical University, Faculty of Medicine, Institute of Heart Diseases , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracjan","family":"Iwanek","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Department of Intensive Cardiac Care, Wroclaw Medical University, Faculty of Medicine, Institute of Heart Diseases , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Baudry","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cobo-Marcos","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Majadahonda, Madrid ,","place":["Spain"]},{"name":"Departamento de Cardiolog\u00eda, Hospital Universitario Puerta de Hierro , Majadahonda, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d2scar","family":"Mir\u00f3","sequence":"additional","affiliation":[{"name":"Emergency Department, Hospital Clinic, IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Dauw","sequence":"additional","affiliation":[{"name":"Cardiovascular Center Aalst, AZORG Hospital , Aalst ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Department of Intensive Cardiac Care, Wroclaw Medical University, Faculty of Medicine, Institute of Heart Diseases , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk ,","place":["Belgium"]},{"name":"Hasselt University, Faculty of Medicine and Life Sciences , Diepenbeek ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Unit, Cardio-Thoracic and Vascular Department, S. Maria alle Scotte Hospital, University of Siena , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili, and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Department of Intensive Cardiac Care, Wroclaw Medical University, Faculty of Medicine, Institute of Heart Diseases , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"2026021721495331300_ejhf70079-bib-0001","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0002","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke Statistics-2023 update: A report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41581-023-00789-8","article-title":"Chronic cardiovascular-kidney disorder: A new conceptual framework","volume":"20","author":"Zoccali","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026021721495331300_ejhf70079-bib-0004","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","article-title":"When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases","volume":"39","author":"Kobayashi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026021721495331300_ejhf70079-bib-0005","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jchf.2024.10.002","article-title":"Advances and challenges in holistic treatment of cardiometabolic kidney disease as one entity","volume":"12","author":"Bozkurt","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0006","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/ndt\/gfac153","article-title":"Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: A comprehensive French nationwide cohort study","volume":"37","author":"Halimi","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026021721495331300_ejhf70079-bib-0007","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ehf2.14601","article-title":"Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease","volume":"11","author":"Sharma","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0008","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1093\/eurheartj\/ehaf457","article-title":"Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCOUTCOMES.110.957571","article-title":"Population impact of heart failure and the most common forms of cancer: A study of 1\u2009162\u2009309 hospital cases in Sweden (1988 to 2004)","volume":"3","author":"Stewart","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026021721495331300_ejhf70079-bib-0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.559016","article-title":"Urinary biomarkers and their potential for the non-invasive detection of endometrial cancer","volume":"10","author":"Njoku","year":"2020","journal-title":"Front Oncol"},{"key":"2026021721495331300_ejhf70079-bib-0011","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1074\/mcp.R800001-MCP200","article-title":"Urine in clinical proteomics","volume":"7","author":"Decramer","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"2026021721495331300_ejhf70079-bib-0012","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/eurheartj\/ehab832","article-title":"Kidney function assessment and endpoint ascertainment in clinical trials","volume":"43","author":"Khan","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0013","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jacc.2024.11.041","article-title":"Standardized definitions of changes in kidney function in trials of heart failure: JACC expert panel from the HF-ARC","volume":"85","author":"Lala","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0014","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0015","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jchf.2022.08.001","article-title":"The need to stop inappropriate coding for acute kidney injury in heart failure","volume":"10","author":"Bozkurt","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0016","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","volume":"12","author":"Beghini","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0018","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0019","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/ard.47.9.759","article-title":"Screening for proteinuria in a rheumatology clinic: Comparison of dipstick testing, 24 hour urine quantitative protein, and protein\/creatinine ratio in random urine samples","volume":"47","author":"Ralston","year":"1988","journal-title":"Ann Rheum Dis"},{"issue":"34","key":"2026021721495331300_ejhf70079-bib-0020","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"33","key":"2026021721495331300_ejhf70079-bib-0021","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0022","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: Standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026021721495331300_ejhf70079-bib-0023","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: Known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"2026021721495331300_ejhf70079-bib-0024","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ejhf.746","article-title":"Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure","volume":"19","author":"Sokolski","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0025","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/eurjhf\/hfs039","article-title":"Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure","volume":"14","author":"Dupont","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0026","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1002\/ehf2.13064","article-title":"Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure","volume":"7","author":"Zymlinski","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0027","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijcard.2021.10.149","article-title":"Distinct renin\/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure","volume":"345","author":"Biegus","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0028","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0029","first-page":"450","article-title":"Response of the kidney to furosemide. I. Effects of salt intake and renal compensation","volume":"102","author":"Wilcox","year":"1983","journal-title":"J Lab Clin Med"},{"key":"2026021721495331300_ejhf70079-bib-0030","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/ehf2.13372","article-title":"Spot urine sodium in acute heart failure: Differences in prognostic value on admission and discharge","volume":"8","author":"Biegus","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0031","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijcard.2017.08.053","article-title":"Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure","volume":"254","author":"Honda","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0032","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","article-title":"Renal sodium avidity in heart failure: from pathophysiology to treatment strategies","volume":"38","author":"Mullens","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0033","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ejhf.2852","article-title":"The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery. The role of furosemide urine excretion on diuretic and natriuretic response in acute heart failure","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0034","first-page":"F374","article-title":"Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment","volume":"248","author":"Kaissling","year":"1985","journal-title":"Am J Physiol"},{"key":"2026021721495331300_ejhf70079-bib-0035","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/ehf2.14920","article-title":"Loop diuretics in heart failure: The objective markers to guide the therapy are needed","volume":"11","author":"Biegus","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0036","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ejhf.1428","article-title":"Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure","volume":"21","author":"Biegus","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0037","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/ejhf.2985","article-title":"Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians","volume":"25","author":"Vazir","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0038","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0039","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.jacc.2023.03.400","article-title":"Natriuretic response to acetazolamide in patients with acute heart failure and volume overload","volume":"81","author":"Verbrugge","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0040","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","article-title":"Natriuresis-guided diuretic therapy in acute heart failure: A pragmatic randomized trial","volume":"29","author":"Ter Maaten","year":"2023","journal-title":"Nat Med"},{"key":"2026021721495331300_ejhf70079-bib-0041","article-title":"Protocolized natriuresis-guided decongestion improves diuretic response: The multicenter ENACT-HF study","volume":"17","author":"Dauw","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0042","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41598-024-51744-x","article-title":"Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure","volume":"14","author":"Guzik","year":"2024","journal-title":"Sci Rep"},{"key":"2026021721495331300_ejhf70079-bib-0043","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ejhf.2053","article-title":"Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients","volume":"23","author":"Biegus","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0044","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ehf2.14883","article-title":"Spot urine sodium-to-creatinine ratio surpasses sodium in identifying poor diuretic response in acute heart failure","volume":"11","author":"Iwanek","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jacc.2020.12.022","article-title":"Natriuretic equation to predict loop diuretic response in patients with heart failure","volume":"77","author":"Rao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0046","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cardfail.2014.03.006","article-title":"Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure","volume":"20","author":"Singh","year":"2014","journal-title":"J Card Fail"},{"key":"2026021721495331300_ejhf70079-bib-0047","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00392-015-0945-x","article-title":"Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: The spironolactone effect","volume":"105","author":"Ferreira","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0048","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12245-017-0143-x","article-title":"Markers of diuretic resistance in emergency department patients with acute heart failure","volume":"10","author":"Doering","year":"2017","journal-title":"Int J Emerg Med"},{"key":"2026021721495331300_ejhf70079-bib-0049","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cardfail.2018.01.009","article-title":"Spot urine sodium as triage for effective diuretic infusion in an ambulatory heart failure unit","volume":"24","author":"Brinkley","year":"2018","journal-title":"J Card Fail"},{"key":"2026021721495331300_ejhf70079-bib-0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ahj.2018.01.013","article-title":"First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization","volume":"203","author":"Luk","year":"2018","journal-title":"Am Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0051","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ehf2.12368","article-title":"Early urine electrolyte patterns in patients with acute heart failure","volume":"6","author":"Collins","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0052","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008166","article-title":"Potential role of natriuretic response to furosemide stress test during acute heart failure","volume":"14","author":"Caravaca P\u00e9rez","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0053","article-title":"The ratio of furosemide dosage to urinary sodium concentration predicts mortality in patients with chronic stable heart failure","volume":"131","author":"Elias","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"2026021721495331300_ejhf70079-bib-0054","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/ejhf.1753","article-title":"Clinical importance of urinary sodium excretion in acute heart failure","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0055","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/ehf2.15275","article-title":"Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis","volume":"12","author":"Cobo Marcos","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0056","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jchf.2019.01.007","article-title":"Natriuretic response is highly variable and associated with 6-month survival: Insights from the ROSE-AHF trial","volume":"7","author":"Hodson","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0057","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/ejhf.2662","article-title":"Assessing intrinsic renal sodium avidity in acute heart failure: Implications in predicting and guiding decongestion","volume":"24","author":"Martens","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0058","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jchf.2019.02.011","article-title":"Urinary sodium profiling in chronic heart failure to detect development of acute decompensated heart failure","volume":"7","author":"Martens","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0059","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ejhf.3693","article-title":"Home-based urinary sodium monitoring via point-of-care testing for personalized diuretic titration in heart failure management: The EASY-STOP study","volume":"27","author":"Meekers","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40119-021-00238-2","article-title":"Chloride in heart failure syndrome: Its pathophysiologic role and therapeutic implication","volume":"10","author":"Kataoka","year":"2021","journal-title":"Cardiol Ther"},{"key":"2026021721495331300_ejhf70079-bib-0061","first-page":"94","article-title":"Neurohormonal activation and renal chloride avidity in acute heart failure: Clinical evidence supporting the \u201cchloride theory","volume":"14","author":"Kataoka","year":"2024","journal-title":"Cardiorenal Med"},{"key":"2026021721495331300_ejhf70079-bib-0062","doi-asserted-by":"crossref","first-page":"14100","DOI":"10.1038\/s41598-024-64747-5","article-title":"The role of urine chloride in acute heart failure","volume":"14","author":"Nawrocka-Millward","year":"2024","journal-title":"Sci Rep"},{"key":"2026021721495331300_ejhf70079-bib-0063","article-title":"The prognostic role of spot urinary sodium and chloride in a cohort of hospitalized advanced heart failure patients: A pilot study","volume":"13","author":"Xanthopoulos","year":"2023","journal-title":"Life (Basel)"},{"key":"2026021721495331300_ejhf70079-bib-0064","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ehf2.15054","article-title":"Urine chloride trajectory and relationship with diuretic response in acute heart failure","volume":"12","author":"Guzik","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0065","doi-asserted-by":"crossref","DOI":"10.34067\/KID.0002502022","article-title":"Fractional excretion of sodium and urea are useful tools in the evaluation of AKI: Commentary","volume":"4","author":"Brown","year":"2023","journal-title":"Kidney360"},{"key":"2026021721495331300_ejhf70079-bib-0066","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0067","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/ehf2.14755","article-title":"Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure","volume":"11","author":"Watanabe","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0068","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ehf2.14327","article-title":"Utility of fractional excretion of urea nitrogen in heart failure patients with chronic kidney disease","volume":"10","author":"Watanabe","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0069","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jchf.2021.12.005","article-title":"Renal compression in heart failure: The renal tamponade hypothesis","volume":"10","author":"Boorsma","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0070","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jacc.2014.11.025","article-title":"The pathophysiological role of interstitial sodium in heart failure","volume":"65","author":"Nijst","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0071","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/hrt.58.3.230","article-title":"Total body electrolyte composition in patients with heart failure: A comparison with normal subjects and patients with untreated hypertension","volume":"58","author":"Cleland","year":"1987","journal-title":"Br Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0072","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: A state-of-the-art review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0073","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/ehf2.14810","article-title":"Heart failure: The grim reaper of the cardio-renal-metabolic triad","volume":"11","author":"\u00d6sterman","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0074","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure: JACC state-of-the-art review","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0075","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/ehf2.14378","article-title":"Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease","volume":"10","author":"Otaki","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0076","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026021721495331300_ejhf70079-bib-0077","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.105.538132","article-title":"Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study","volume":"112","author":"Arnl\u00f6v","year":"2005","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0078","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M23-2814","article-title":"Association of albuminuria with chronic kidney disease progression in persons with chronic kidney disease and normoalbuminuria: A cohort study","volume":"177","author":"Verma","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026021721495331300_ejhf70079-bib-0079","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/eurjpc\/zwae189","article-title":"The relationship between low levels of albuminuria and mortality among adults without major cardiovascular risk factors","volume":"31","author":"Claudel","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamacardio.2017.4987","article-title":"Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction","volume":"3","author":"Boer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0081","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jacc.2007.12.048","article-title":"Novel metabolic risk factors for incident heart failure and their relationship with obesity: The MESA (Multi-Ethnic Study of Atherosclerosis) study","volume":"51","author":"Bahrami","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0082","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","article-title":"High-normal albuminuria and risk of heart failure in the community","volume":"58","author":"Blecker","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2026021721495331300_ejhf70079-bib-0083","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0084","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026021721495331300_ejhf70079-bib-0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ejhf.778","article-title":"The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction","volume":"19","author":"Nayor","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0086","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ejhf.1971","article-title":"Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: A SPRINT substudy","volume":"23","author":"Vaduganathan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0087","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0088","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"2026021721495331300_ejhf70079-bib-0089","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.109.929661","article-title":"Multimarker approach for the prediction of heart failure incidence in the community","volume":"122","author":"Velagaleti","year":"2010","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0090","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0091","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCHEARTFAILURE.109.881805","article-title":"Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: Data from the GISSI-Heart Failure trial","volume":"3","author":"Masson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0092","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: Prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"key":"2026021721495331300_ejhf70079-bib-0093","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0094","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/eurjhf\/hfs001","article-title":"Urinary albumin excretion in heart failure with preserved ejection fraction: An interim analysis of the CHART 2 study","volume":"14","author":"Miura","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0095","first-page":"527","article-title":"Albuminuria: Associated with heart failure severity and impaired clinical outcomes","volume":"36","author":"Shuvy","year":"2020","journal-title":"Can J Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0096","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jchf.2014.05.016","article-title":"Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction","volume":"2","author":"Katz","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0097","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI103127","article-title":"The pathogenesis of proteinuria in the acutely congested kidney","volume":"34","author":"Wegria","year":"1955","journal-title":"J Clin Invest"},{"key":"2026021721495331300_ejhf70079-bib-0098","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1172\/JCI103024","article-title":"Urinary protein excretion and renal hemodynamic adjustments during orthostasis in patients with acute and chronic renal diseases","volume":"33","author":"Lathem","year":"1954","journal-title":"J Clin Invest"},{"key":"2026021721495331300_ejhf70079-bib-0099","first-page":"74","article-title":"Trajectory of urine albumin-creatinine ratio in patients with acute heart failure","volume":"14","author":"Ll\u00e0cer","year":"2024","journal-title":"Cardiorenal Med"},{"key":"2026021721495331300_ejhf70079-bib-0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/CIRCHEARTFAILURE.112.000152","article-title":"Early evolution and correlates of urine albumin excretion in patients presenting with acutely decompensated heart failure","volume":"6","author":"Koyama","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0101","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s00380-022-02025-y","article-title":"Urine albumin-to-creatinine ratio on admission predicts early rehospitalization in patients with acute decompensated heart failure","volume":"37","author":"Matsumoto","year":"2022","journal-title":"Heart Vessels"},{"key":"2026021721495331300_ejhf70079-bib-0102","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/eurheartj\/ehac528","article-title":"Albuminuria as a marker of systemic congestion in patients with heart failure","volume":"44","author":"Boorsma","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ejhf.3094","article-title":"Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance","volume":"26","author":"Ioannou","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0104","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002333","article-title":"Influence of titration of neurohormonal antagonists and blood pressure reduction on renal function and decongestion in decompensated heart failure","volume":"9","author":"Kula","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0105","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/ejhf.3423","article-title":"Decongestion in acute heart failure: Is it time to change diuretic-centred paradigm?","volume":"26","author":"Biegus","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0106","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/ejhf.2967","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0107","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026021721495331300_ejhf70079-bib-0108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacc.2024.04.055","article-title":"Effects of rapid uptitration of neurohormonal blockade on effective, sustainable decongestion and outcomes in STRONG-HF","volume":"84","author":"Biegus","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2026021721495331300_ejhf70079-bib-0109","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2026021721495331300_ejhf70079-bib-0110","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"2026021721495331300_ejhf70079-bib-0111","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2026021721495331300_ejhf70079-bib-0112","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2026021721495331300_ejhf70079-bib-0113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2026021721495331300_ejhf70079-bib-0114","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0115","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2026021721495331300_ejhf70079-bib-0116","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: A meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721495331300_ejhf70079-bib-0117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026021721495331300_ejhf70079-bib-0118","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0022-3565(25)38470-3","article-title":"Losartan improves the natriuretic response to ANF in rats with high-output heart failure","volume":"268","author":"Abassi","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"2026021721495331300_ejhf70079-bib-0119","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/01.HYP.22.3.339","article-title":"Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects","volume":"22","author":"Burnier","year":"1993","journal-title":"Hypertension"},{"issue":"10","key":"2026021721495331300_ejhf70079-bib-0120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"2026021721495331300_ejhf70079-bib-0121","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0122","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/dom.12600","article-title":"Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2026021721495331300_ejhf70079-bib-0123","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"2026021721495331300_ejhf70079-bib-0124","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2337\/diacare.23.3.377","article-title":"Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction","volume":"23","author":"Capes","year":"2000","journal-title":"Diabetes Care"},{"issue":"5","key":"2026021721495331300_ejhf70079-bib-0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0126","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: The PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0127","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/ejhf.3265","article-title":"Reduced congestion and improved response to a fluid\/sodium challenge in chronic heart failure patients after initiation of sacubitril\/valsartan: The NATRIUM-HF study","volume":"26","author":"Mebazaa","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2026021721495331300_ejhf70079-bib-0129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0130","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1093\/eurheartj\/ehae561","article-title":"In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: The PREMIER trial","volume":"45","author":"Tanaka","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0131","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0132","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0133","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0134","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0135","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"19","key":"2026021721495331300_ejhf70079-bib-0136","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: The PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"2026021721495331300_ejhf70079-bib-0137","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008537","article-title":"Pitfalls in using estimated glomerular filtration rate slope as a surrogate for the effect of drugs on the risk of serious adverse renal outcomes in clinical trials of patients with heart failure","volume":"14","author":"Packer","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0138","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0139","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin inhibitors in heart failure: The science, mechanism of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"2026021721495331300_ejhf70079-bib-0140","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1161\/01.HYP.0000190585.54734.48","article-title":"Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes","volume":"46","author":"Bakris","year":"2005","journal-title":"Hypertension"},{"key":"2026021721495331300_ejhf70079-bib-0141","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejim.2013.08.711","article-title":"Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure","volume":"25","author":"Ferreira","year":"2014","journal-title":"Eur J Intern Med"},{"key":"2026021721495331300_ejhf70079-bib-0142","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026021721495331300_ejhf70079-bib-0143","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0144","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2022.12.045","article-title":"Effect of eplerenone on clinical stability of Japanese patients with acute heart failure","volume":"374","author":"Kobayashi","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ehjcvp\/pvaa132","article-title":"Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): A multicentre, randomized, double-blind, placebo-controlled trial","volume":"8","author":"Asakura","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026021721495331300_ejhf70079-bib-0146","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021721495331300_ejhf70079-bib-0147","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1210\/clinem\/dgad144","article-title":"Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes","volume":"108","author":"Oiwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021721495331300_ejhf70079-bib-0148","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.08.005","article-title":"Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial","volume":"47","author":"Brandt-Jacobsen","year":"2021","journal-title":"Diabetes Metab"},{"key":"2026021721495331300_ejhf70079-bib-0149","first-page":"236","article-title":"Mineralocorticoid receptor antagonist combined with SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: A meta-analysis of randomized trials","volume":"56","author":"Ferreira","year":"2025","journal-title":"Am J Nephrol"},{"issue":"9","key":"2026021721495331300_ejhf70079-bib-0150","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"2026021721495331300_ejhf70079-bib-0151","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: A mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026021721495331300_ejhf70079-bib-0152","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0153","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: The FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"2026021721495331300_ejhf70079-bib-0154","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0156","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0157","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1002\/ehf2.15294","article-title":"SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper","volume":"12","author":"Ferreira","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0158","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: Diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0159","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.0000000000000269","article-title":"Empagliflozin in heart failure: Regional nephron sodium handling effects","volume":"35","author":"Rao","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026021721495331300_ejhf70079-bib-0160","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30%-50% of renal glucose reabsorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"2026021721495331300_ejhf70079-bib-0161","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ejhf.2086","article-title":"Empagliflozin and renal sodium handling: An intriguing smart osmotic diuretic","volume":"23","author":"Mullens","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0162","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0163","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0164","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0165","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0166","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: A prospective randomized controlled study","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0167","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","article-title":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics","volume":"44","author":"Yeoh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0168","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: The RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0169","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00392-022-02119-7","article-title":"The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: Results from a placebo-controlled randomised trial","volume":"112","author":"Kolwelter","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0170","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0171","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026021721495331300_ejhf70079-bib-0172","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0173","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.125.076575","article-title":"Dapagliflozin in patients hospitalized for heart failure: Primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2 inhibitors in patients hospitalized for heart failure","volume":"152","author":"Berg","year":"2025","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0174","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2026021721495331300_ejhf70079-bib-0175","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721495331300_ejhf70079-bib-0176","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2215\/CJN.10180916","article-title":"Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function","volume":"12","author":"Petrykiv","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2026021721495331300_ejhf70079-bib-0177","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0178","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721495331300_ejhf70079-bib-0179","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0180","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jamacardio.2022.2924","article-title":"Association of empagliflozin treatment with albuminuria levels in patients with heart failure: A secondary analysis of EMPEROR-Pooled","volume":"7","author":"Ferreira","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"15","key":"2026021721495331300_ejhf70079-bib-0181","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"2026021721495331300_ejhf70079-bib-0182","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0183","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jdi.12063","article-title":"Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes","volume":"4","author":"He","year":"2013","journal-title":"J Diabetes Investig"},{"key":"2026021721495331300_ejhf70079-bib-0184","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"2026021721495331300_ejhf70079-bib-0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2026021721495331300_ejhf70079-bib-0186","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"2026021721495331300_ejhf70079-bib-0187","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0188","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"2026021721495331300_ejhf70079-bib-0189","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0190","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: Pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"2026021721495331300_ejhf70079-bib-0191","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure","volume":"75","author":"Marso","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2026021721495331300_ejhf70079-bib-0192","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0193","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: A secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"2026021721495331300_ejhf70079-bib-0194","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrcardio.2014.215","article-title":"Diuretic response in acute heart failure \u2013 pathophysiology, evaluation, and therapy","volume":"12","author":"Maaten","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0195","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0196","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","article-title":"Combination of loop diuretics with thiazide-type diuretics in heart failure","volume":"56","author":"Jentzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2026021721495331300_ejhf70079-bib-0197","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: The CLOROTIC trial","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0198","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/ki.2015.249","article-title":"Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease","volume":"88","author":"Morales","year":"2015","journal-title":"Kidney Int"},{"key":"2026021721495331300_ejhf70079-bib-0199","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2026021721495331300_ejhf70079-bib-0200","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(14)70030-0","article-title":"Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial","volume":"2","author":"Kwakernaak","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721495331300_ejhf70079-bib-0201","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0202","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0203","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2026021721495331300_ejhf70079-bib-0204","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026021721495331300_ejhf70079-bib-0205","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0206","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0207","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2013.04.073","article-title":"Effects of nesiritide and predictors of urine output in acute decompensated heart failure: Results from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure)","volume":"62","author":"Gottlieb","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0208","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021721495331300_ejhf70079-bib-0209","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/jama.2013.282190","article-title":"Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE Acute Heart Failure randomized trial","volume":"310","author":"Chen","year":"2013","journal-title":"JAMA"},{"key":"2026021721495331300_ejhf70079-bib-0210","first-page":"83","article-title":"Effect of low-dose administration of carperitide for acute heart failure: The LASCAR-AHF trial","volume":"14","author":"Honda","year":"2025","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026021721495331300_ejhf70079-bib-0211","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2215\/CJN.0000000000000188","article-title":"Combination diuretic therapy to counter renal sodium avidity in acute heart failure: Trials and tribulations","volume":"18","author":"Kazory","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021721495331300_ejhf70079-bib-0212","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4070\/kcj.2014.44.3.156","article-title":"A pilot study of target weight guided treatment in acute heart failure using ultrafiltration or usual care: Effect on sodium removal","volume":"44","author":"Chung","year":"2014","journal-title":"Korean Circ J"},{"key":"2026021721495331300_ejhf70079-bib-0213","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.jacc.2011.10.910","article-title":"Diuretics and ultrafiltration in acute decompensated heart failure","volume":"59","author":"Felker","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0214","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jchf.2015.08.005","article-title":"Aquapheresis versus intravenous diuretics and hospitalizations for heart failure","volume":"4","author":"Costanzo","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026021721495331300_ejhf70079-bib-0215","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jacc.2006.07.073","article-title":"Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure","volume":"49","author":"Costanzo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0216","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt.1625","article-title":"Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium","volume":"28","author":"Dieterle","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2026021721495331300_ejhf70079-bib-0217","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","article-title":"Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction","volume":"72","author":"Tromp","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0218","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/eurheartj\/ehac248","article-title":"An update on global epidemiology in heart failure","volume":"43","author":"Becher","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0219","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12265-023-10356-y","article-title":"Urinary marker profiles in heart failure with reduced versus preserved ejection fraction","volume":"17","author":"Streng","year":"2024","journal-title":"J Cardiovasc Transl Res"},{"key":"2026021721495331300_ejhf70079-bib-0220","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0221","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2022.05.054","article-title":"Heart failure with normal LVEF in BIOSTAT-CHF","volume":"364","author":"Baumhove","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026021721495331300_ejhf70079-bib-0222","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ejhf.3230","article-title":"Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100\u2009000 patients in the Swedish Heart Failure Registry","volume":"26","author":"Settergren","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2026021721495331300_ejhf70079-bib-0223","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: An individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension"},{"key":"2026021721495331300_ejhf70079-bib-0224","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.27396","article-title":"Diagnostic yield of population-based screening for chronic kidney disease in low-income, middle-income, and high-income countries","volume":"4","author":"Tonelli","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026021721495331300_ejhf70079-bib-0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110535","article-title":"Primary care detection of chronic kidney disease in adults with type-2 diabetes: The ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease)","volume":"9","author":"Szczech","year":"2014","journal-title":"PLoS One"},{"key":"2026021721495331300_ejhf70079-bib-0226","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ahj.2023.07.014","article-title":"Randomized controlled trial of urinE chemiStry guided aCute heArt faiLure treATmEnt (ESCALATE): Rationale and design","volume":"265","author":"Cox","year":"2023","journal-title":"Am Heart J"},{"key":"2026021721495331300_ejhf70079-bib-0227","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2024.08.044","article-title":"Rationale and design of the DECONGEST (Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment) study","volume":"31","author":"Vanhentenrijk","year":"2025","journal-title":"J Card Fail"},{"key":"2026021721495331300_ejhf70079-bib-0228","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/ejhf.3429","article-title":"Nurse-led diuretic titration via a point-of-care urinary sodium sensor in patients with acute decompensated heart failure (EASY-HF): A single-centre, randomized, open-label study","volume":"26","author":"Meekers","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2026021721495331300_ejhf70079-bib-0229","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jama.2009.2","article-title":"BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial","volume":"301","author":"Pfisterer","year":"2009","journal-title":"JAMA"},{"key":"2026021721495331300_ejhf70079-bib-0230","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.117.029882","article-title":"NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?)","volume":"137","author":"Stienen","year":"2018","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2372\/66833617\/eurjhf_27_11_2372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2372\/66833617\/eurjhf_27_11_2372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:50:23Z","timestamp":1771383023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/11\/2372\/8470258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":230,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,3]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.70079","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"2025-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}